MyCartis is a privately held immunodiagnostics company, providing next generation solutions to detect and quantify protein biomarker signatures by providing precise and personalized novel clinical information for the benefit of researchers, clinicians and CRO’s.
Mycartis’ Evalution® platform with Dynamic Multi-Analyte Technology (DMAT®) inside, provides a unique multiplex biomarker platform in combination with the required sensitivity and dynamic range for the integrated analysis of protein biomarkers. DMAT® utilizes proprietary disk-shaped microparticles which carry a unique code and can be functionalized with specific proteins, antibodies, nucleic acids or other molecules. Thanks to the optimized binding kinetics in the microfluidic channels and to the fact that all binding reactions can be followed in real-time, DMAT® provides the perfect platform to assess binding interactions and hence the potency and avidity of the protein-antibody interaction.
In addition to proprietary product development, MyCartis provides an open technology and software, enabling custom development and straightforward deployment of multiplex assays by partners on the platform.